The prescription of opiate medications is increasing. Individuals with inflammatory bowel diseases (IBD) can develop serious complications from opiate use, but few data are available on the prescription of these drugs to patients with IBD. We examined trends in prescriptions of opiates and their association with all-cause mortality in individuals with IBD.
C hronic abdominal pain is a common symptom in inflammatory bowel disease (IBD), linked to abdominal distention, intestinal inflammation, or to such complications as abscesses or fistulae.
1 As well as abdominal pain, individuals with IBD can experience musculoskeletal pain from associated arthropathies and are at higher risk of chronic widespread pain and fibromyalgia. 2 Pain management in IBD is complicated by clinically important gastrointestinal (GI) side effects that are associated with many of the available analgesics. Opiate medications, in particular, are associated with established adverse effects on the GI tract. [3] [4] [5] When opiate medications are used for individuals with IBD, there are concerns about precipitating toxic dilatation during an acute flare, causing narcotic bowel 6 and potentially masking a disease flare. Opiates are also discouraged for long-term use because of tachyphylaxis and hyperalgesia, which often cause patients to seek increasing doses, which in turn can predispose to more frequent and severe side effects.
in prescriptions for strong opiates from 2005-2012. 9 Multiple complications and side effects of opiate use have been observed including hospitalization, psychosocial problems, and mortality. 10, 11 There is a paucity of data on the trend in prescription of opiate medications and their association with survival for individuals with IBD. Most of the available data are derived from case series in tertiary referral centers, which may not be representative of the entire IBD disease spectrum.
The aims were to explore trends in the prescription of opiate medications in individuals with IBD, and to assess the association between opiate medication prescription and all-cause mortality in individuals with IBD.
Methods

Data Sources and Participants
The primary care database ResearchOne was used for this study. 12 ResearchOne holds deidentified clinical and administrative information from the electronic health records of approximately 6 million individuals (>10% of the total population) in England. Prescriptions are issued electronically and clinical data are prospectively entered using Clinical Terms version 3 codes (Read codes). 13 
Inclusion and Exclusion Criteria
We included all individuals at the extraction date (September 14, 2014) with a Read code for IBD (Supplementary Table 1 ) in their primary care record. Subjects were classified as Crohn's disease (CD) and ulcerative colitis (UC) when only Read codes for these IBD subtypes were recorded. We selected incident cases of IBD, defined as having the first recorded entry for IBD at least 1 year after registering at a ResearchOne practice. This excluded prevalent cases of IBD, without continuous ResearchOne clinical and prescription data. Individuals who had undergone a colectomy for UC were excluded.
For all individuals, we extracted a defined set of data items, including date of birth (mm/yyyy), gender, date of death (mm/yyyy), general practitioner (GP) registrations, Index of Multiple Deprivation 14 of residence, diagnoses of IBD and relevant comorbidities (including smoking status), ethnicity, and prescriptions (including repeat prescriptions). British National Formulary (https://www.evidence.nhs.uk/formulary/bnf/ current) headings and subheadings were used to identify the medication classes. Individuals were followed up from their IBD diagnosis to either death or the extraction date. Opiate medications were identified and then divided into separate categories for analysis 8 
:
"Any opiate medication" defined as any prescription of an opiate medication.
"Codeine" defined as any prescription of codeine without another opiate.
"Tramadol" defined as any individual ever prescribed tramadol with or without codeine.
"Strong opiates" defined as individuals who had received a prescription for a strong opiate either alone or in combination with other opiate medications. Strong opiates were defined as prescriptions of (1) morphine, (2) oxycodone, (3) fentanyl, (4) buprenorphine, (5) methadone (as a surrogate marker for nonprescription opiates), (6) hydromorphone, and (7) pethidine.
A prescription from primary care in the United Kingdom is typically for a 28-day course. 9 To investigate a potential dose response we defined 3 categories of opiate prescription density: (1) none or infrequent use, defined as <1 prescription per calendar year of opiate use; (2) moderate opiate use, defined as 1-3 prescriptions per calendar year of opiate use; and (3) heavy opiate use, defined as >3 prescriptions per calendar year of opiate use.
The calendar year of opiate use was defined as the number of years from the first opiate prescription after an IBD diagnosis to the last date of an opiate prescription before death or the extraction date. Opiate use in the 60 days before death or extraction was excluded to try and account for use in end-of-life care. 15 
Statistical Analysis
We explored trends in opiate prescriptions for all individuals with IBD in 4-year blocks from January 1, 1990, to December 31, 2013, using the chi-square for trend as a significance test. The number of alive, incident subjects being prescribed an opiate was divided by the total number of incident subjects in the 4-year block to produce a proportion ever prescribed an opiate. Separate trends were produced for each class of opiate medication. We also examined the proportion of individuals being prescribed an opiate medication at 1, 5, and 10 years after a diagnosis of IBD.
Propensity scores can reduce the bias in estimating treatment effects and reduce the likelihood of confounding when analyzing nonrandomized, observational data. 16 We calculated a propensity score estimating the conditional probability of being prescribed an opiate medication based on predefined characteristics, which may influence opiate prescription or the primary outcome of death. Age at diagnosis, duration of IBD, and the English Index of Multiple Deprivation score 14 were used as continuous variables. A lower Index of Multiple Deprivation score equates to more deprivation and has been shown to correlate with increased morbidity and all-cause mortality in the United Kingdom. 17 To account for comorbidity we produced an estimate of the Charlson score (Supplementary Table 2) . 18 We calculated a similar, weighted score and used a cutoff of 2 as a modest estimate of comorbidity. We included GI surgical resections at any time in the study period, because these individuals may be more likely to receive analgesics or have a more severe disease phenotype. Smoking history was recorded as ever and never smoked, or a third category of those with smoking data missing. We adjusted for known surrogate markers of IBD severity including corticosteroid medications given within 90 days of IBD diagnosis 19 and also immunomodulator use, namely azathioprine, 6-mercaptopurine, and methotrexate. 20 We stratified individuals according to their year of diagnosis (before the year 1993, 1993-1999, 2000-2006, and 2007-2014) to account for changing clinical practice, and population health factors that may affect mortality. We also included the percentage of those with IBD who were prescribed an opiate medication in each GP practice as a continuous variable to account for variation in prescribing practice among GPs, which may influence the prescription of an opiate. We calculated a separate propensity score for receiving each class of opiate medication for CD and UC.
We compared the characteristics of opiate users and nonusers for the unmatched and propensity score--matched groups, using the chi-square test for categorical data, the 2 sampled Student t test for continuous, parametric variables and Mann-Whitney U test for nonparametric variables (Table 1) . Variables with a significant association were included as independent confounders in the final, adjusted survival model.
We performed a propensity score matched, Cox proportional hazards regression analysis to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for all-cause mortality. Survival time was taken as the time to death in days from the first IBD diagnosis for each individual. Opiate nonusers and users were matched on a 1:1 basis with no replacement and a caliper width of 0.2 standard deviations of the propensity score logit. 21 We repeated these analyses for each of our opiate classes. We performed a further analysis comparing strong opiate users with users of any other class of opiate medication (codeine or tramadol) because opiate users are likely to share characteristics, and potential confounding factors, based on the need for analgesia. All of these analyses were performed separately for individuals with CD and UC. Cox proportional hazards assumption was tested by visually inspecting log-log and Kaplan-Meier versus predicted survival plots.
Sensitivity Analyses
To test the validity of our results we performed several additional analyses. We added the propensity score variables to the Cox proportional hazards model. We repeated the primary analysis for strong versus any other opiates increasing the matching frequency of 1:2 and 1:3 to increase the statistical power. We repeated the analyses for all subjects with a Read code for IBD, which included those with a code for indeterminate colitis. Finally, we repeated the primary analysis after excluding subjects who had undergone previous GI resectional surgery.
For all of our analyses we considered a P value of < .05 as significant. Data management and statistical analysis was conducted using Python 2.5.2 (Python Software Foundation, Hampton, NH), R (R Foundation for Statistical Computing; www.R-project.org), and STATA version 12 (StataCorp LP, College Station, TX).
ResearchOne has received a favorable opinion from National Health Service Research Ethics Committee (11/ NE/0184) and the UK National Information Governance Board for Health and Social Care. Our study has National Health Service Research Ethics Committee (14/WM/01/ 26) and local research and development (GA14/11077) approval.
Results
Our study cohort comprised 3517 individuals with CD and 5349 with UC ( Figure 1 ). The demographics of the unmatched and matched cohorts for opiate users and nonusers for each IBD subtype are shown in Table 1 . Any opiate users with CD or UC had a longer duration of IBD, were older at diagnosis, female sex, smokers, had undergone GI resectional surgery, had an estimated Charlson comorbidity score >2, and were registered with a GP with a higher percentage of those with IBD having ever been prescribed an opiate (all P < .005). Opiate users with UC were less likely to have been given a steroid prescription within 90 days of diagnosis (P ¼ .04), but more likely to have ever been prescribed an immunomodulator (P < .005). These characteristics were similar when comparing each opiate medication subtype (Supplementary Table 3 ). After 1:1 propensity score matching there were no differences between opiate users and nonusers for each opiate class (Table 1 and  Supplementary Table 3 ) so no additional covariates were included in our primary survival analyses. The number who died during the follow-up was significantly higher for opiate users compared with nonusers for CD (11% vs 6%; P < .005) and UC (12% vs 5%; P < .005).
The number of those with IBD receiving any opiate prescription increased from 10% in the period 1990-1993, to 30% in 2010-2013 (chi-square for trend, P < .005) (Figure 2 ). There was a similar, significant increase for codeine (chi-square for trend, P ¼ .008), tramadol (P < .005), and strong opiates (P < .005) when analyzed separately. The proportion of individuals being prescribed an opiate medication was 14%, 26%, and 34% after 1, 5, and 10 years of diagnosis for CD and 9%, 20%, and 27% for individuals with UC.
We found a significant association between heavy use of any opiate and increased premature mortality for individuals with UC (HR, 1.67; 95% CI, 1.25-2.23) ( Table 2 ). There was a similar association for heavy use of codeine (HR, 1.83; 95% CI, 1.10-3.05). The largest association was for the heavy use of strong opiates in individuals with UC (HR, 3.30; 95% CI, 1.77-6.18) with a significant association also seen for moderate use (HR, 2.44; 95% CI, 1.16-5.15). There was no association for prescriptions of tramadol at any prescription density. (Table 2) . When comparing strong opiates with any opiates, heavy use had the largest association with increased premature mortality for CD (HR, 2.04; 95% CI, 1.14-3.65) and UC (HR, 2.47; 95% CI, 1.41-4.33).
We performed a series of sensitivity analyses including the propensity score variables in the Cox proportional hazards model, increasing the matching ratio to 1:2 and 1:3, including individuals with a Read code for indeterminate colitis, and excluding those who had undergone previous GI resectional surgery. There were no changes in the associations seen ( Supplementary  Tables 4-7 ).
Discussion
Our study is the largest population-based study of opiate use in subjects with IBD. We have shown a significant increase in the prescription of opiates since 1990, with 30% of individuals with IBD being prescribed an opiate medication during the years 2010-2013. A recent study, from a US insurance database, reported 3.8% of CD subjects becoming chronic opiate users within 2 years of diagnosis. 22 Another US study has recently reported opiate use in a US ambulatory care visit. 23 They reported no change in the use of opiate prescriptions from 2003 to 2011 where a diagnosis code for IBD was recorded. A limitation with this study is that the primary reason for attendance is likely to be for pain rather than IBD when an opiate prescription is issued. Their results also conflict with the published literature on the rising tide of opiate prescriptions for cancer and noncancer associated pain. 8, 24 Earlier studies reported prescriptions in up to a sixth of patients admitted to hospital. 25, 26 Our results suggest higher use; however, we have a much longer duration of follow-up, and prescription data from primary care are likely to be a better reflection of long-term medication habits.
Prescriptions of codeine in UC and strong opiates in both CD and UC were associated with increased all-cause premature mortality. There seems to be a dose association because heavy opiate use showed the largest associations. Opiates are known to be associated with mortality for non-cancer-related pain. 10, 11 It is plausible to support a similar role in IBD, being associated with adverse outcomes, such as infection, 27 and higher health care utilization. 28 There has been 1 previous populationbased study from Manitoba, Canada in 2014 involving 4217 subjects, with similar results to our own, reporting a strong association of heavy opioid use with increased mortality (odds ratio, 2.82; 95% CI, 1.58-5.02). 29 We included a large sample of 3517 CD and 5349 UC subjects with an average follow-up of 9 years from IBD diagnosis. More than 98% of UK residents are registered with a GP so the study cohort is likely to be representative of the full clinical spectrum of IBD. 30 Previous studies have shown that Read code entries were >90% accurate in an analysis of IBD in a similar UK primary care database, the General Practice Research Datalink (now called the Clinical Practice Research Datalink). 31 Studies using secondary or tertiary care data are likely to have an inherent referral bias, typically including those with more severe disease. We produced different groups of opiate prescription density to investigate a potential dose response for the opiate medications. There was an increased strength of association between increased premature mortality and strong opiate use for those with both UC and CD compared with nonusers or the use of the weaker opiates, codeine and tramadol. Cumulative dose of opiates could not be readily determined from the data because the dose and quantity associated with each prescription were subject to unstructured recording. There does not seem to be an association with the use of tramadol alone or in combination with codeine.
There are several limitations to this study. Our results relate to the prescription of opiates and we do not know whether these prescriptions were obtained or taken as prescribed. Opiate use may be the cause or the effect of potential residual confounding factors. Previous studies have shown that opiate use in IBD is associated with fistulating disease and lower quality-of-life scores, 32 psychological illness, history of abuse, and substance abuse. 5 We were unable to control for these factors in our study. We do not know the reason for the opiate prescription, which would enable us to identify factors with an association bias. However, we included comorbidity, deprivation, gender, age at diagnosis, smoking, and GP prescribing practices in our propensity score model and the results were sustained. We did not have phenotypic data on disease extent and the use of anti-tumor necrosis factor medication, which is typically used in more severe disease and may be a potential confounder. It is administered from hospital specialists, so prescribing data are not consistently available in primary care databases. However, widespread use for maintenance therapy was not adopted in the United Kingdom until 2010 33 and between 2002 and 2010 episodic treatment was available but uptake was low. Less than 3% of those with IBD in the United Kingdom were prescribed an anti-tumor necrosis factor in 2010. 34 Codeine can also be prescribed to control diarrheal symptoms, which may be a marker of disease severity in IBD, and we displayed an association with heavy codeine use and mortality in UC. The stronger opiates are not indicated for controlling diarrhea. We are unable to account for over-the-counter or illicit opiate medication use; however, higher strength opiates are controlled medications in the United Kingdom necessitating a prescription and we have attempted to control for illicit opiate use by including methadone, which is prescribed by GPs in England for opiate detoxification programs, in our strong opiate analyses.
A limitation with our trend analyses is that there will be an increase in the use of electronic prescriptions throughout the study period, which could account for some of the increase seen in opiate prescriptions. This must be taken into account when interpreting the results, although previous studies have validated electronic prescribing in UK primary care prescription records with 95% concordance being shown in prescriptions from 1990. 35 
Conclusions
Opiate prescriptions are increasing worldwide in individuals with chronic noncancer pain, and individuals with IBD can now be included in this group. There are justifiable concerns about opiate prescriptions, with established dose-dependent associations with morbidity and mortality. 36 These effects have prompted some jurisdictions to implement guidelines to limit opiate use, 37, 38 and run education programs for prescribers. 39, 40 We believed that there should be the same pharmacovigilance applied to prescribing opiates for those with IBD, especially because heavy use (>3 prescriptions per calendar year) was associated with the worst outcomes. Whether the opiates are attributing to this increased mortality within the defined time period or are associated with another causative factor is not certain. Designing and conducting a large-scale randomized controlled trial may not be feasible. Despite the limitations of observational data, population datasets may be the best method to investigate a potential effect.
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